Impact of platelet reactivity to adenosine diphosphate before implantation of drug-eluting stents on subsequent adverse cardiac events in patients with stable angina

Circulation Journal

Volumn 76, Issue 3, 2012, Pages 641-649

  Motoda, Chikaaki ^a   Ueda, Hironori ^b   Hayashi, Yasuhiko ^c   Toyofuku, Mamoru ^c   Okimoto, Tomokazu ^c   Otsuka, Masaya ^c   Tamekiyo, Hiromichi ^c   Kawase, Tomoharu ^c   Kihara, Yasuki ^a  

^a HIROSHIMA UNIVERSITY   (Japan)

^b HIROSHIMA PREFECTURAL HOSPITAL   (Japan)

^c TSUCHIYA GENERAL HOSPITAL   (Japan)

Author keywords

Anti platelet therapy; Drug eluting stent; Percutaneous coronary intervention; Platelet reactivity to ADP; Revascularization

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; CLOPIDOGREL; PACLITAXEL; RAPAMYCIN; TICLOPIDINE;

AGED; ANGIOCARDIOGRAPHY; ARTICLE; BLEEDING; DISEASE ASSOCIATION; DRUG ELUTING STENT; FEMALE; FOLLOW UP; HEART DEATH; HEART INFARCTION; HUMAN; JAPANESE; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; PREVALENCE; REVASCULARIZATION; STABLE ANGINA PECTORIS; STENT THROMBOSIS; THROMBOCYTE AGGREGATION;

ADENOSINE DIPHOSPHATE; AGED; AGED, 80 AND OVER; ANGINA, STABLE; ASPIRIN; DRUG-ELUTING STENTS; FEMALE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL ISCHEMIA; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; TICLOPIDINE;

EID: 84857588954     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.cj-11-0435     Document Type: Article

References (41)

1. Geisler T, Langer H, Wydymus M, Gohring K, Zurn C, Bigalke B, et al. Low response to clopidogrel is associated with cardiovascular outcome after coronary stent implantation. Eur Heart J 2006; 27: 2420-2425.
2. Buonamici P, Marcucci R, Migliorini A, Gensini GF, Santini A, Paniccia R, et al. Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis. J Am Coll Cardiol 2007; 49: 2312-2317.
3. Patti G, Nusca A, Mangiacapra F, Gatto L, D'Ambrosio A, Di Sciascio G. Point-of-care measurement of clopidogrel responsiveness predicts clinical outcome in patients undergoing percutaneous coronary intervention results of the ARMYDA-PRO (antiplatelet therapy for reduction of myocardial damage during angioplasty-platelet reactivity predicts outcome) study. J Am Coll Cardiol 2008; 52: 1128-1133.
4. Marcucci R, Gori AM, Paniccia R, Giusti B, Valente S, Giglioli C, et al. Cardiovascular death and nonfatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reactivity to ADP detected by a point-of-care assay: A 12-month follow-up. Circulation 2009; 119: 237-242.
5. Gurbel PA, Bliden KP, Hiatt BL, O'Connor CM. Clopidogrel for coronary stenting: Response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation 2003; 107: 2908-2913.
6. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, Alfonso F, Macaya C, Bass TA, et al. Variability in individual responsiveness to clopidogrel: Clinical implications, management, and future perspectives. J Am Coll Cardiol 2007; 49: 1505-1516.
7. Mega JL, Close SL, Wiviott SD, Shen L, Hockett RD, Brandt JT, et al. Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med 2009; 360: 354-362.
8. Gurbel PA, Becker RC, Mann KG, Steinhubl SR, Michelson AD. Platelet function monitoring in patients with coronary artery disease. J Am Coll Cardiol 2007; 50: 1822-1834.
9. Tsukahara K, Kimura K, Morita S, Ebina T, Kosuge M, Hibi K, et al. Impact of high-responsiveness to dual antiplatelet therapy on bleeding complications in patients receiving drug-eluting stents. Circ J 2010; 74: 679-685.
10. Tamekiyo H, Hayashi Y, Toyofuku M, Ueda H, Sakuma T, Okimoto T, et al. Clinical outcomes of sirolimus-eluting stenting after rotational atherectomy. Circ J 2009; 73: 2042-2049.
11. Okada T, Hayashi Y, Toyofuku M, Imazu M, Otsuka M, Sakuma T, et al. One-year clinical outcomes of dialysis patients after implantation with sirolimus-eluting coronary stents. Circ J 2008; 72: 1430-1435.
12. van der Zwet PM, Pinto IM, Serruys PW, Reiber JH. A new approach for the automated definition of path lines in digitized coronary angiograms. Int J Card Imaging 1990; 5: 75-83.
13. Ryan TJ, Faxon DP, Gunnar RM, Kennedy JW, King SB 3rd, Loop FD, et al. Guidelines for percutaneous transluminal coronary angioplasty. A report of the American College of Cardiology/American Heart Association Task Force on Assessment of Diagnostic and Therapeutic Cardiovascular Procedures (Subcommittee on Percutaneous Transluminal Coronary Angioplasty). Circulation 1988; 78: 486-502.
14. Sudo T, Ito H, Ozeki Y, Kimura Y. Estimation of anti-platelet drugs on human platelet aggregation with a novel whole blood aggregometer by a screen filtration pressure method. Br J Pharmacol 2001; 133: 1396-1404.
15. Ozeki Y, Sudo T, Toga K, Nagamura Y, Ito H, Ogawa T, et al. Characterization of whole blood aggregation with a new type of aggregometer by a screen filtration pressure method. Thromb Res 2001; 101: 65-72.
16. Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, van Es GA, et al. Clinical end points in coronary stent trials: A case for standardized definitions. Circulation 2007; 115: 2344-2351.
17. Stone GW, Ellis SG, Cox DA, Hermiller J, O'Shaughnessy C, Mann JT, et al. One-year clinical results with the slow-release, polymer-based, paclitaxel-eluting TAXUS stent: The TAXUS-IV trial. Circulation 2004; 109: 1942-1947.
18. Born GV, Haslam RJ, Goldman M. Comparative effectiveness of adenosine analogues as inhibitors of blood-platelet aggregation and as vasodilators in man. Nature 1965; 205: 678-680.
19. Sibbing D, Braun S, Morath T, Mehilli J, Vogt W, Schomig A, et al. Platelet reactivity after clopidogrel treatment assessed with point-ofcare analysis and early drug-eluting stent thrombosis. J Am Coll Cardiol 2009; 53: 849-856.
20. Tabuchi A, Taniguchi R, Takahashi K, Kondo H, Kawato M, Morimoto T, et al. Action of aspirin on whole blood-aggregation evaluated by the screen filtration pressure method. Circ J 2008; 72: 420-426.
21. Bonello L, Tantry US, Marcucci R, Blindt R, Angiolillo DJ, Becker R, et al. Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. J Am Coll Cardiol 2010; 56: 919-933.
22. Matetzky S, Shenkman B, Guetta V, Shechter M, Bienart R, Goldenberg I, et al. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation 2004; 109: 3171-3175.
23. Daemen J, Wenaweser P, Tsuchida K, Abrecht L, Vaina S, Morger C, et al. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: Data from a large two-institutional cohort study. Lancet 2007; 369: 667-678.
24. Kimura T, Morimoto T, Nakagawa Y, Tamura T, Kadota K, Yasumoto H, et al. Antiplatelet therapy and stent thrombosis after sirolimus-eluting stent implantation. Circulation 2009; 119: 987-995.
25. Marzocchi A, Saia F, Piovaccari G, Manari A, Aurier E, Benassi A, et al. Long-term safety and efficacy of drug-eluting stents: Two-year results of the REAL (REgistro AngiopLastiche dell'Emilia Romagna) multicenter registry. Circulation 2007; 115: 3181-3188.
26. Mutoh M, Ishikawa T, Hasuda T, Okada H, Endo A, Miyanaga S, et al. Predictors of target lesion revascularization and documented stent thrombosis beyond 30 days after sirolimus-eluting stent implantation: Retrospective analysis in consecutive 1,070 angiographic follow-up lesions. Circ J 2007; 71: 1328-1331.
27. Schulz S, Sibbing D, Braun S, Morath T, Mehilli J, Massberg S, et al. Platelet response to clopidogrel and restenosis in patients treated predominantly with drug-eluting stents. Am Heart J 2010; 160: 355-361.
28. Ha-Duong NT, Dijols S, Macherey AC, Goldstein JA, Dansette PM, Mansuy D. Ticlopidine as a selective mechanism-based inhibitor of human cytochrome P450 2C19. Biochemistry 2001; 40: 12112-12122.
29. Li M, Zhang Y, Ren H, Zhu X. Effect of clopidogrel on the inflammatory progression of early atherosclerosis in rabbits model. Atherosclerosis 2007; 194: 348-356.
30. Virmani R, Kolodgie FD, Farb A, Lafont A. Drug eluting stents: Are human and animal studies comparable? Heart 2003; 89: 133-138.
31. Kotani J, Awata M, Nanto S, Uematsu M, Oshima F, Minamiguchi H, et al. Incomplete neointimal coverage of sirolimus-eluting stents: Angioscopic findings. J Am Coll Cardiol 2006; 47: 2108-2111.
32. Chen BX, Ma FY, Luo W, Ruan JH, Xie WL, Zhao XZ, et al. Neointimal coverage of bare-metal and sirolimus-eluting stents evaluated with optical coherence tomography. Heart 2008; 94: 566-570.
33. Ueda H, Imazu M, Hayashi Y, Ono K, Yasui W, Yamakido M. Immunohistochemical analysis of hepatocyte growth factor in human coronary atherectomy specimens: Comparison with transforming growth factor beta isoforms. Virchows Arch 1997; 430: 407-415.
34. Ali S, Davis MG, Becker MW, Dorn GW 2nd. Thromboxane A2 stimulates vascular smooth muscle hypertrophy by up-regulating the synthesis and release of endogenous basic fibroblast growth factor. J Biol Chem 1993; 268: 17397-17403.
35. Ferns GA, Raines EW, Sprugel KH, Motani AS, Reidy MA, Ross R. Inhibition of neointimal smooth muscle accumulation after angioplasty by an antibody to PDGF. Science 1991; 253: 1129-1132.
36. Crowley ST, Dempsey EC, Horwitz KB, Horwitz LD. Plateletinduced vascular smooth muscle cell proliferation is modulated by the growth amplification factors serotonin and adenosine diphosphate. Circulation 1994; 90: 1908-1918.
37. Sata M, Saiura A, Kunisato A, Tojo A, Okada S, Tokuhisa T, et al. Hematopoietic stem cells differentiate into vascular cells that participate in the pathogenesis of atherosclerosis. Nat Med 2002; 8: 403-409.
38. Evans DJ, Jackman LE, Chamberlain J, Crosdale DJ, Judge HM, Jetha K, et al. Platelet P2Y12 receptor influences the vessel wall response to arterial injury and thrombosis. Circulation 2009; 119: 116-122.
39. Oikawa Y, Yajima J, Costa MA, Matsuno S, Akabane M, Funada R, et al. Intravascular ultrasound, angioscopic and histopathological characterisation of heterogeneous patterns of restenosis after sirolimuseluting stent implantation: Insights into potential "thromborestenosis" phenomenon. EuroIntervention 2010; 6: 380-387.
40. Breet NJ, van Werkum JW, Bouman HJ, Kelder JC, Ruven HJ, Bal ET, et al. Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation. JAMA 2010; 303: 754-762.
41. Sawada T, Shinke T, Shite J, Honjo T, Haraguchi Y, Nishio R, et al. Impact of cytochrome P450 2C19*2 polymorphism on intra-stent thrombus after drug-eluting stent implantation in Japanese patients receiving clopidogrel. Circ J 2011; 75: 99-105.